Compare Cytokinetics Inc (CYTK) vs United Microelectronics Corp (UMC) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Cytokinetics Inc vs United Microelectronics Corp — how do they compare? Cytokinetics Inc trades at $61.95 (market cap $8.62B), while United Microelectronics Corp trades at $23 (market cap $58.02B). The key difference: United Microelectronics Corp is far larger — about 6.7× Cytokinetics Inc's market cap, and United Microelectronics Corp pays a 1.76% dividend while Cytokinetics Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Cytokinetics Inc for 19 Days and United Microelectronics Corp for 42 Days on average.
| CYTK | UMC | |
|---|---|---|
Market Cap | $8.62B | $58.02B |
Volume | 2,594,626 | 11,897,809 |
Sector | Health | Technology |
52-Week High | $87.26 | $28.02 |
52-Week Low | $54.76 | $7.02 |
Typical Hold Time | 19 Days | 42 Days |
Enterprise Value | $8.72B | $55.10B |
Dividend Yield | — | 1.76% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Cytokinetics (CYTK) trades at $61.12, down 0.37% on the day, with a bearish technical signal from moving averages despite some oversold RSI readings. The company reported a net loss of $784.96 million on $88.04 million revenue in 2025, with a negative net income margin of -1,321.12% in 2026. Recent news highlights clinical progress for aficamten in hypertrophic cardiomyopathy and executive stock sales.
Wall Street maintains strong bullish sentiment with a 97.14% buy rating and $112.60 consensus price target, but high cash burn, persistent losses, and insider selling pose significant risks. The stock's outlook hinges on successful commercialization of its heart failure pipeline amid substantial financial and competitive pressures.
United Microelectronics (UMC) trades at $23.31, up 0.52% with a bullish technical signal despite mixed moving averages. The company shows strong profitability with 32.75% net income margin and 21.03% ROE, though revenue growth has slowed from 2022 peaks. Recent earnings beats and positive 2026 projections suggest operational strength, while analyst consensus remains cautious with 53% hold ratings.
UMC presents a mixed outlook with strong fundamentals offset by valuation concerns. The stock's 250% annual gain creates near-term resistance, while projected 2026 earnings growth of 103% offers upside potential. Key risks include semiconductor cyclicality and AI spending volatility, requiring careful position sizing despite intrinsic value estimates near $29.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Cytokinetics Inc
Cytokinetics is a biopharmaceutical company focused on muscle biology. It develops muscle activators and inhibitors as potential treatments for debilitating diseases where muscle performance is compromised or declining.
Read more on CYTK →About United Microelectronics Corp
Founded in 1980, United Microelectronics is the world's third-largest dedicated chip foundry, with 7% market share in 2021, according to Gartner, after TSMC and GlobalFoundries. UMC's headquarters are in Hsinchu, Taiwan, and it operates 12 fabs in Taiwan, Mainland China, Japan and Singapore, with additional sales offices in Europe, the U.S. and South Korea. UMC features a diverse customer base including Texas Instruments, MediaTek, Qualcomm, Broadcom, Xilinx and Realtek, supplying a wide range of products applied in communications, display, memory, automotive and more. UMC employs about 20,000 people.
Read more on UMC →
